Wide Ranks

MBRX

Moleculin Biotech, Inc.

2.69

Top Statistics
Market Cap 8 M Forward PE -0.5095 Revenue Growth 0.00 %
Current Ratio 2.08 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0330 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 9 M Total Cash Per Share 3.13 Total Debt 390000
Total Debt To Equity 5.21 Current Ratio 2.08 Book Value Per Share 3.36
All Measures
Short Ratio 109.00 % Message Board Id finmb_320105606 Shares Short Prior Month 171524
Return On Equity -1.41 City Houston Uuid 99d8deac-7003-3e25-96dc-75c8e887f9ca
Previous Close 2.60 First Trade Date Epoch Utc 1 B Book Value 3.36
Total Debt 390000 Volume 19469 Price To Book 0.8011
Last Split Date 1 B Fifty Two Week Low 0.4000 Total Cash Per Share 3.13
Shares Short Previous Month Date 1 B Target Median Price 18.00 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Target Mean Price 18.00
Net Income To Common -30150000 Short Percent Of Float 0.0187 Implied Shares Outstanding 3 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 96610
Average Volume10days 96610 Total Cash 9 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0334 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.60 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.56 Open 2.55
Free Cashflow -13241125 State TX Dividend Yield 0.00 %
Return On Assets -0.5745 Time Zone Short Name EST Trailing Eps -12.04
Day Low 2.54 Address1 5300 Memorial Drive Shares Outstanding 3 M
Price Hint 4 Target High Price 28.00 Website https://moleculin.com
52 Week Change 3.49 Average Volume 41342 Forward Eps -5.87
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 168.20 %
Last Split Factor 1:15 Regular Market Day High 2.75 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 5.21 Fifty Two Week High 6.24
Day High 2.75 Shares Short 54134 Regular Market Open 2.55
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0180 Operating Cashflow -24186000 Currency USD
Time Zone Full Name America/New_York Market Cap 8 M Is_nasdaq_100 False
Zip 77007 Quote Type EQUITY Industry Biotechnology
Long Name Moleculin Biotech, Inc. Regular Market Day Low 2.54 Held Percent Institutions 0.1534
Current Price 2.69 Address2 Suite 950 Enterprise To Ebitda 0.0330
Financial Currency USD Current Ratio 2.08 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 2 M
Two Hundred Day Average 3.12 Enterprise Value -939902 Forward PE -0.5095
Regular Market Volume 19469 Ebitda -28787000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.

Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.

The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.

In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.

The company was incorporated in 2015 and is headquartered in Houston, Texas.